Forest and Nycomed to Present Results from Six Roflumilast Posters
May 10 2010 - 2:00AM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX) and Nycomed today
announced that they will present data from six roflumilast posters
during the American Thoracic Society (ATS) International Conference
being held in New Orleans, LA, May 14 through May 19, 2010.
Roflumilast is an investigational anti-inflammatory, oral
medication for the treatment of Chronic Obstructive Pulmonary
Disease (COPD) associated with chronic bronchitis in patients at
risk of exacerbations. Included in the poster presentations are
additional results from the 12-month and 6-month roflumilast
studies previously published in The Lancet.
The scheduled times and titles of presentations are:
- Roflumilast and its active
metabolite inhibit LPS-induced cytokine production from human lung
macrophages by a PGE2-dependent mechanism: poster (D7) available on
Sunday, May 16, 8:15 am – 4:00 pm CDT, with presentation by A.
Buenestado, PhD, 10:45 am – 12:30 pm
- Efficacy of roflumilast in
patients receiving concomitant treatments for chronic obstructive
pulmonary disease over 12 months: poster (F72) available on
Tuesday, May 18, 8:15 am – 4:00 pm CDT, with presentation by N.A.
Hanania, MD, MS, 10:45 am – 12:30 pm
- Time course and reversibility of
weight decrease with roflumilast, a PDE4 inhibitor: poster (F78)
available on Tuesday, May 18, 8:15 am – 4:00 pm CDT, with
presentation by F.J. Martinez, MD, MS, 10:45 am – 12:30 pm
- Effects of roflumilast, a PDE4
inhibitor, on body composition in chronic obstructive pulmonary
disease: poster (B64) available on Tuesday, May 18, 8:15 am – 4:00
pm CDT, with presentation by E.F.M. Wouters, MD, PhD, 10:45 am –
12:30 pm
- Effects of roflumilast, a PDE4
inhibitor, on glucose homeostasis in patients with treatment-naïve
diabetes: poster (B62) available on Tuesday, May 18, 8:15 am – 4:00
pm CDT, with presentation by E.F.M. Wouters, MD, PhD, 10:45 am –
12:30 pm
- Roflumilast N-oxide partially
prevents the loss of ciliated human airway epithelial cells
secondary to incubation with cigarette smoke extracts in vitro:
poster (B68) available on Tuesday, May 18, 8:15 am – 4:00 pm CDT,
with presentation by J. Milara, PhD, 10:45 am – 12:30 pm
About COPD
COPD is an under-diagnosed, progressive lung disease that is the
fourth leading cause of death in the U.S. Of the six leading causes
of death in the United States, COPD and diabetes mellitus are the
only diseases for which the mortality rate has increased over the
past 30 years, with COPD mortality almost doubling since 1970.
Approximately 12 million people in the U.S. are currently diagnosed
with COPD and an additional 12 million are likely to have the
disease and not know it.
Symptoms of COPD include breathlessness, chronic cough and
excessive production of phlegm. A significant worsening of symptoms
called an exacerbation can last several weeks and may lead to
hospitalization. Exacerbations are distressing and dangerous events
resulting in increased patient anxiety, worsening health status,
lung function decline, and increased risk of death.
About roflumilast (Daxas®)
Roflumilast is a phosphodiesterase 4 (PDE4) enzyme inhibitor
that targets the underlying inflammation associated with COPD. If
approved, roflumilast, a once-a-day oral tablet, will be the first
in an entirely new class of treatment for COPD. Roflumilast is not
a steroid.
About Nycomed
Nycomed is a privately owned global pharmaceutical company with
a differentiated portfolio focused on branded medicines in
gastroenterology, respiratory and inflammatory diseases, pain,
osteoporosis and tissue management. An extensive range of OTC
products completes the portfolio.
Its R&D is structured around partnerships and in-licensing
is a cornerstone of the company's growth strategy.
Nycomed employs 12,000 associates worldwide, and its products
are available in more than 100 countries. It has strong platforms
in Europe and in fast-growing markets such as Russia/CIS and Latin
America. While the US and Japan are commercialised through
best-in-class partners, Nycomed plans to further strengthen its own
position in key Asian markets.
Headquartered in Zurich, Switzerland, the company generated
total sales of €3.2 billion in 2009 and an adjusted EBITDA of
€1.1 billion.
For more information, visit www.nycomed.com.
About Forest Laboratories
Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical
company with a long track record of building partnerships and
developing and marketing products that make a positive difference
in people's lives. In addition to its well-established franchises
in therapeutic areas of the central nervous and cardiovascular
systems, Forest's current pipeline includes product candidates in
all stages of development and across a wide range of therapeutic
areas. The Company is headquartered in New York, NY. To learn more
about Forest Laboratories, visit www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024